Last updated 2026-07-27
TL;DR
No study has tracked enclomiphene use beyond about 6 months, so true long term data doesn't exist yet. Trials that far show it raises testosterone and LH while largely preserving sperm counts and testicular size, unlike injectable TRT. It's not FDA approved; what you get is compounded. The main known risks are mood changes, vision disturbances, and unclear long term cardiovascular and clotting effects.
What is enclomiphene and how is it different from clomiphene?
Clomiphene citrate (brand name Clomid) is actually a mixture of two isomers: enclomiphene and zuclomiphene, roughly 60/40 by weight. Enclomiphene is the trans-isomer, the one that does most of the work at the hypothalamus, blocking estrogen receptor feedback so the brain ramps up GnRH, then LH and FSH, which pushes the testes to make more testosterone. Zuclomiphene is the cis-isomer, it's weakly estrogenic, has a much longer half-life, and sticks around in fat tissue for weeks. Some researchers think zuclomiphene accumulation is part of why long term clomiphene use has been linked to mood complaints and visual side effects in case reports. Enclomiphene as a standalone drug was developed specifically to strip out the zuclomiphene and give men (and researchers) a cleaner look at what the active isomer does on its own. The idea was a testosterone-raising therapy without the sperm-suppressing, testicle-shrinking effect you get from injectable testosterone, because unlike TRT, enclomiphene doesn't shut down the hypothalamic-pituitary-gonadal axis; it stimulates it [1]. That distinction matters for anyone comparing it to Enclomiphene Direct dosage protocols versus a standard TRT injection schedule. TRT replaces testosterone from outside the system and the brain responds by dialing down its own signal (LH and FSH drop, and so does sperm production). Enclomiphene tells the brain to make more of its own signal instead.
Is enclomiphene FDA approved, and does that affect long term safety data?
No. Enclomiphene is not FDA approved as a standalone drug in the United States. The compound went through clinical development under the name Androxal, run by Repros Therapeutics, aiming for an indication in secondary hypogonadism. Repros ran Phase 3 trials (the ZA-304 and ZA-305 studies) but the program never reached FDA approval and the company's later attempts to revive it did not succeed either [2]. Because there's no approved product, there's no FDA-mandated long term post-marketing surveillance for enclomiphene the way there is for an approved drug. What men can legally obtain in the US is compounded enclomiphene, prepared by a licensed compounding pharmacy under a prescription, not a mass-manufactured, FDA-approved tablet. Compounded drugs are regulated differently: the FDA doesn't independently verify the safety or efficacy of each compounded formulation the way it does for an approved NDA product, and compounding pharmacies operate under sections 503A or 503B of the Food, Drug & Cosmetic Act rather than under a standard drug approval [1]. Practically, this means the strongest human data on enclomiphene tops out around the length of the Androxal trials, several months, not years. Anyone telling you they know what enclomiphene does to a man's body after 5 or 10 years of continuous use is guessing. That's an honest gap, not a marketing footnote.
What did the actual enclomiphene trials find over 3 to 6 months?
The published Phase 2/3 data on enclomiphene in men with secondary hypogonadism runs mostly 3 to 6 months. A widely cited Phase 2 trial (Wiehle et al., published in BJU International, 2014) compared enclomiphene citrate to topical testosterone gel over 3 and 6 months in men with secondary hypogonadism. It found enclomiphene restored serum testosterone to normal ranges while, unlike testosterone gel, maintaining or even increasing sperm counts and LH/FSH levels [3]. The study's own conclusion: "Enclomiphene citrate increased LH, FSH, and total testosterone while maintaining or increasing sperm counts... in contrast, testosterone gel suppressed LH, FSH, and sperm counts" [3]. That's the core evidence behind the fertility-preservation claim, and it's real, but it's a 6-month window in a specific population (men with secondary/functional hypogonadism, generally with intact testicular function), not a lifetime guarantee for every man on the drug. Over that 3-6 month window, reported side effects were generally mild: headache, some reports of mood changes or irritability, occasional hot flashes, and in a minority of men, changes in liver enzymes or lipid values that generally weren't clinically alarming in the trial reports. Nobody has published a controlled trial following enclomiphene users past 6 months, so anything past that point comes from clinician experience and inference, not trial data.
Does enclomiphene really preserve fertility better than TRT long term?
The mechanism strongly favors fertility preservation, and the available data backs that up over the trial durations studied, but nobody should promise permanent fertility protection from any drug, including this one. TRT (testosterone injections, gels, pellets) suppresses the hypothalamic-pituitary-gonadal axis. The brain sees exogenous testosterone, assumes the testes are already producing plenty, and cuts LH and FSH output. Over months, that drop in LH/FSH shrinks the testes and can crash sperm counts, sometimes down to azoospermia (zero sperm) in a meaningful share of men on long term TRT [4]. Recovery after stopping TRT is possible for many men but isn't guaranteed and can take many months to years, and isn't universal, particularly with longer TRT duration and older age [4]. Enclomiphene works the opposite direction: it raises LH and FSH, which is why the trial data shows preserved or increased sperm counts rather than suppression [3]. That's a real, mechanistically sound advantage for men who want to raise testosterone without shutting down sperm production, for example men still planning to have children. What the evidence doesn't support: a guarantee that fertility stays fully intact in every man, over every duration, at every dose. Individual response varies, some men on any hormone-modulating therapy see LH/FSH responses that are weaker than the group averages in a trial. If fertility is a near-term priority, a semen analysis before starting and periodically during treatment is the only way to actually know your own response, not an assumption based on the drug's average effect in a study population.
What are the known short and medium term side effects of enclomiphene?
Across the available trial and case report data, the most commonly reported effects include: - Mood changes: irritability, anxiety, or low mood in a subset of users, similar to complaints seen with clomiphene
- Hot flashes, at rates lower than seen with clomiphene in some comparative reports
- Headache
- Mild elevations in blood pressure or lipid markers in some men, requiring periodic bloodwork
- Visual disturbances (blurred vision, floaters), which is a known class effect flagged prominently on clomiphene's label and considered a reason to stop the drug if it occurs [5] The FDA label for clomiphene citrate (Clomid), the closest approved reference point since enclomiphene itself was never approved, carries a specific warning: "Visual symptoms may occur... patients who experience these symptoms should discontinue therapy" [5]. Because enclomiphene shares the same estrogen-receptor mechanism at the hypothalamic and possibly retinal level, this warning is generally treated as relevant to enclomiphene users too, even without enclomiphene-specific labeling. Bloodwork protocols matter here. Anyone starting therapy should get baseline labs (total and free testosterone, LH, FSH, estradiol, lipids, liver function) and repeat them a few months in, which is a big part of why working with a provider who orders and reviews labs (rather than buying loose vials with no oversight) is the safer path. That's the model behind Enclomiphene Direct dosage protocols, provider-reviewed dosing rather than guesswork.
What don't we know about enclomiphene's long term risks?
A lot, honestly. Here's the specific gap list: - Cardiovascular risk over years of use: no long term cardiovascular outcome trial exists for enclomiphene specifically. TRT itself has a mixed and debated long term cardiovascular safety record (the TRAVERSE trial, published in the New England Journal of Medicine in 2023, found testosterone replacement in middle-aged and older men with hypogonadism was non-inferior to placebo for major cardiovascular events over a median of 22 months) , but that trial studied testosterone, not enclomiphene, and can't be extrapolated directly.
- Bone density: TRT has documented effects on bone mineral density; whether enclomiphene's more modest estradiol modulation has any meaningful long term bone effect isn't established either way.
- Clotting risk: SERMs as a drug class (including tamoxifen, used in breast cancer treatment) carry documented associations with venous thromboembolism in some populations. Enclomiphene's clotting risk profile specifically, over long term use, hasn't been isolated in a dedicated study.
- Vision changes with years of use: the clomiphene label warning is based on shorter term use; whether risk accumulates with years of continuous use is unknown for enclomiphene specifically.
- Effects on prostate, bone marrow, or other estrogen-sensitive tissue over a decade-plus of use: unstudied. The honest summary a good clinician should give you: enclomiphene has a reasonable safety signal over the 6-month windows it's actually been studied in, and a mechanism that looks favorable compared to exogenous TRT for fertility and testicular size. Beyond that window, it's inference from mechanism and from the broader SERM/clomiphene literature, not direct proof.
How does enclomiphene compare to TRT and to clomiphene on side effect profile?
| Factor | Enclomiphene (compounded) | Clomiphene citrate (Clomid, approved) | Injectable TRT | |
|---|---|---|---|---|
| FDA approval status | Not approved standalone; compounded only | Approved (for female infertility; male use is off-label) [5] | Approved for hypogonadism | |
| Effect on LH/FSH | Increases | Increases | Suppresses | |
| Effect on sperm count | Preserved/increased in trials [3] | Mixed; zuclomiphene component linked to more side effects | Often suppressed, can reach azoospermia [4] | |
| Testicular size | Preserved | Generally preserved | Often decreases | |
| Longest controlled trial duration | About 6 months [3] | Decades of use, but mostly studied in women; male long term data is thinner | Years (TRAVERSE: ~22 months median) | |
| Visual disturbance warning | Assumed relevant (shared mechanism) | Explicit FDA label warning [5] | Not a class effect | |
| Long term cardiovascular data | None specific to the drug | Limited in men | TRAVERSE found non-inferiority to placebo for major CV events | The practical takeaway: enclomiphene looks like the cleaner version of clomiphene (less zuclomiphene-related mood and visual complaint burden, in theory) and a fertility-friendlier alternative to TRT mechanistically. But it's the newest and least-studied of the three in terms of total accumulated years of data, precisely because it never got approved and mainstreamed the way TRT and clomiphene did. |
Who should avoid enclomiphene or be extra cautious long term?
Men with a history of blood clots, stroke, or significant cardiovascular disease should discuss the SERM class's clotting associations with their prescriber before starting, given the unresolved long term data gap. Men with primary hypogonadism (testicular failure, as opposed to secondary/hypothalamic-pituitary hypogonadism) generally aren't good candidates, since enclomiphene works by stimulating the pituitary-testicular axis, and if the testes themselves can't respond, there's nothing for the drug to stimulate. Men with a personal history of vision problems, especially retinal issues, should flag this before starting given the class warning on visual disturbances. Anyone planning to conceive within the next several months should get a baseline semen analysis, more than take the fertility-preservation claim on faith, since individual response varies and the strongest supporting study only ran 6 months [3]. Liver disease is another consideration worth a direct conversation with a prescriber, since periodic liver enzyme monitoring is standard practice with SERM-class drugs generally.
What monitoring makes sense if you're using enclomiphene long term?
Given the data gap past 6 months, monitoring is really the only rational hedge available. A reasonable baseline and follow-up schedule looks like this: - Before starting: total and free testosterone, LH, FSH, estradiol, complete blood count, a full metabolic panel (liver and kidney function), lipid panel, and a semen analysis if fertility is a near-term goal
- 6-8 weeks in: repeat testosterone, LH, FSH, and estradiol to confirm response and guide dose adjustment (see Enclomiphene Direct dosage calculator for how dose relates to expected labs)
- Every 3-6 months on ongoing therapy: repeat the full panel, plus a symptom check specifically for mood changes and any visual disturbance, given the class warning
- Annually, or sooner if any symptoms appear: reassess whether continued therapy still makes sense, especially for men who've been on it multiple years, given that nobody has trial data past roughly 6 months to reassure you that a given individual trajectory is 'normal' This is also where cycling comes up. Some men run enclomiphene continuously; others use defined Enclomiphene Direct cycle length protocols with planned breaks, partly as a hedge against the unknown long term picture and partly to reassess whether the body's own axis has adjusted. There's no trial comparing continuous versus cyclic use for long term safety, so this is a clinical judgment call, not a settled protocol.
Where does Enclomiphene fit into this picture?
Enclomiphene Direct provides a provider-reviewed path to compounded enclomiphene, meaning a licensed clinician reviews your history and labs before prescribing, rather than you sourcing a vial with no oversight. It's worth being clear about what that does and doesn't mean: it doesn't make the drug FDA-approved (it isn't, and no compounded enclomiphene product is), and it doesn't create new long term safety data that doesn't otherwise exist. What it does is put a prescriber and a compounding pharmacy partner between you and the drug, which is the appropriate baseline for anything with this much remaining uncertainty in the literature. If you're getting started, the practical next steps are working out a sensible starting protocol (Enclomiphene Direct dosage), understanding how to reconstitute Enclomiphene Direct correctly if you're using an injectable formulation, and getting the injection technique right via Enclomiphene Direct how to inject and Enclomiphene Direct injection sites.
Frequently asked questions
Does enclomiphene cause permanent side effects?
No study has followed enclomiphene long enough to answer that with certainty. Trials run about 6 months and show reversible effects (mood changes, headache, occasional vision symptoms) that resolve on stopping in most reports. Permanent effects haven't been documented, but the absence of long term studies means this is an evidence gap, not a clean bill of health.
Can enclomiphene shrink your testicles like TRT does?
The mechanism works opposite to TRT: enclomiphene raises LH and FSH, which stimulate rather than suppress testicular function, and trial data shows testicular size and sperm counts are generally preserved, unlike with injectable testosterone, which commonly shrinks testes over months of use [4][5].
Is enclomiphene FDA approved?
No. Enclomiphene was developed as Androxal by Repros Therapeutics and went through Phase 3 trials, but the program never gained FDA approval [2]. What's available in the US is compounded enclomiphene from a licensed pharmacy, prescribed off-label, not an approved manufactured drug.
What's the difference between enclomiphene and clomiphene?
Clomiphene citrate is a mixture of two isomers, roughly 60% enclomiphene and 40% zuclomiphene. Enclomiphene is the isomer that does most of the testosterone-raising work; zuclomiphene is weakly estrogenic, has a much longer half-life, and is thought to contribute more to mood and visual side effects seen with clomiphene.
Does enclomiphene affect fertility long term?
The strongest trial data (6 months) shows enclomiphene preserves or increases sperm counts, unlike TRT, because it raises rather than suppresses LH/FSH [4]. No study has confirmed fertility outcomes beyond that window, so this is a mechanistic and short-term evidence advantage, not a guaranteed lifetime outcome.
What are the most common side effects of enclomiphene?
Trial and case data show headache, mood changes (irritability, anxiety), occasional hot flashes, and in a subset of users, mild changes in liver enzymes or lipids. Vision disturbances are a known class warning carried on clomiphene's label and generally treated as relevant to enclomiphene given the shared mechanism [6].
Is there a long term cardiovascular risk with enclomiphene?
Nobody knows for certain; no dedicated long term cardiovascular outcome trial exists for enclomiphene. The TRAVERSE trial found testosterone replacement therapy was non-inferior to placebo for major cardiovascular events over about 22 months [7], but that studied testosterone, not enclomiphene, so it can't be directly extrapolated.
How long have people actually been studied on enclomiphene?
The longest published controlled trials run about 6 months (the Wiehle et al. Phase 2 study in BJU International compared enclomiphene to testosterone gel at 3 and 6 month marks) [4]. Nothing longer has been published, so anything past 6 months is clinical inference, not trial evidence.
Can women take enclomiphene?
Enclomiphene as a standalone drug was developed and studied for male secondary hypogonadism, not for female use. Clomiphene citrate (the enclomiphene/zuclomiphene mixture) is FDA-approved for ovulation induction in women, but that's a different, approved product with its own distinct label and evidence base [6].
Do you need bloodwork while on enclomiphene long term?
Yes, this is standard practice: baseline testosterone, LH, FSH, estradiol, liver function, and lipids before starting, then repeat testing around 6-8 weeks in and every 3-6 months on ongoing therapy, given how much of the long term picture still depends on individual monitoring rather than trial reassurance.
Does enclomiphene raise estrogen?
Enclomiphene blocks estrogen receptors at the hypothalamus rather than raising estradiol directly, though total testosterone increases can modestly raise estradiol via aromatization in some men. Baseline and follow-up estradiol testing is part of standard monitoring to catch anyone whose levels rise more than expected.
What happens if you stop enclomiphene after years of use?
There's no published long term discontinuation study specifically for enclomiphene. Given its stimulatory mechanism (it doesn't suppress the pituitary-testicular axis the way TRT does), the expectation is a smoother return to baseline than after TRT, but this is inference from mechanism, not confirmed multi-year outcome data.
Sources
- Wiehle et al., BJU International, mechanism review: Enclomiphene stimulates the hypothalamic-pituitary-gonadal axis rather than suppressing it
- ClinicalTrials.gov, Repros Therapeutics Androxal Phase 3 studies: Androxal (enclomiphene) completed Phase 3 trials but did not reach FDA approval
- Endocrine Society / NIH-affiliated review on testosterone therapy and spermatogenesis suppression: Exogenous testosterone therapy suppresses LH/FSH and can lead to azoospermia with variable recovery over time
- FDA-approved labeling, Clomid (clomiphene citrate): Clomiphene citrate label warns that visual symptoms warrant discontinuation of therapy
- Lincoff et al., New England Journal of Medicine 2023, TRAVERSE trial: Testosterone replacement therapy was non-inferior to placebo for major adverse cardiovascular events over a median 22 months